

Addiction Toxicology Case Conference
Atypical Buprenorphine Initiation & Combinations: Using Opioid Affinity to Your Advantage

Case 1: Persistent Naloxone Infusion in an Opioid-Dependent Patient

Case 2: Buprenorphine Precipitated Withdrawal

Release Date: February 9, 2024

Expiration Date: February 9, 2025

Activity Overview

A Deep Dive into Complex Addiction Cases with Leading Experts!

The ACMT Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

Target Audience

This activity is designed for an audience of Physicians and Nurses.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

- Describe the use of buprenorphine in reducing the need for prolonged naloxone infusion.

Criteria for Success

To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at kwolynski@akhcme.com



CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of *AMA PRA Category 1 Credit(s)*™ awarded.

Nurses

Credit being awarded: 1.00 ANCC contact hours.

Commercial Support

There is no commercial support for this activity.

Faculty / Planner Disclosures


Moderators:



Gloria J. Baciewicz, MD (Moderator)

Addiction Psychiatrist
Strong Recovery

Since 1986, Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester's Recovery Center of Excellence.



Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director of Toxicology and of the Toxicology Consults

University of Rochester Medical Center, Rochester, NY

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center in Rochester New York. He is Board Certified in Medical Toxicology and Addiction Medicine and practices in Addiction Toxicology with a mix of clinical, research, teaching, and other professional work. Dr. Wiegand has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and he is currently serving on the Board of Directors for the American Society of Addiction Medicine (ASAM) completing a term on the Executive Counsel as Vice President of ASAM. He begins a two-year term as Treasurer of ASAM in April 2023. Dr. Wiegand founded and led the Toxicology service at URM until 2022 when he became Director of Addiction Medicine and Director of Addiction Medicine Consults also at URM in the Department of Emergency Medicine. Dr. Wiegand has served as Fellowship Director for the URM Combined Addiction Medicine Fellowship, and he is the Fellowship Director for the URM Medical Toxicology fellowship expecting to formally begin once accredited, in July of 2023.

Panelists:




Chase Jones, DO

Medical Toxicology Fellow

Lehigh Valley Health Network

Dr. Chase Jones is an emergency medicine specialist in Bethlehem, PA. He is currently a Medical Toxicology Fellow at Lehigh Valley Health.



Joshua Nogar, MD

Assistant Professor of Emergency Medicine, Zucker School of Medicine

Hofstra/Northwell Health

Dr. Josh Nogar grew up in the High Desert of New Mexico but has been a New Yorker for 16 years. Dr. Nogar received his medical degree from the New York University School of Medicine in 2005, completed a residency in Emergency Medicine at the University of New Mexico in 2009, and a fellowship in Medical Toxicology at the University of California San Diego in 2011. He has been faculty in the department of Emergency Medicine & Medical Toxicology at North Shore University Hospital since 2011, in Long Island, NY. He has been the Medical Toxicology Fellowship Director at Northwell Health since 2016, and his areas of specific interest include fellow education, metabolic uncouplers, overdose trends, and addiction medicine. He is dedicated to helping trainees achieve their individual career goals, as well as adapting his training program to the changing scope of practice for Medical Toxicologists, as well as the needs to individual learners. Outside of work, Dr. Nogar enjoys spending time with his wife & children. He is an avid fly-fisherman.

Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner/Reviewer: has nothing to disclose.

Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has nothing to disclose.

AKH Planners and Reviewers: have nothing to disclose.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.